Literature DB >> 11823322

Genotype and phenotype in Alzheimer's disease.

Clive Holmes1.   

Abstract

BACKGROUND: Patients with Alzheimer's disease show a wide variation in clinical phenotype. Genetic research has been largely concerned with the role of mutations or common variants as risk factors for the disease. Do genetic factors also influence clinical phenotype? AIMS: To examine the evidence that genetic factors influence the clinical expression of the disease in addition to influencing risk.
METHOD: A selective review was made of the key literature.
RESULTS: Mutations in three genes, coding for amyloid precursor protein, presenilin-1 and presenilin-2, and a common variation (epsilon4) in another gene, APOE, have been shown to lead to an earlier development of the disease. More recently, genetic association and twin studies have suggested a role for genetic factors in the development of other aspects of clinical phenotype, notably the appearance of non-cognitive symptoms.
CONCLUSIONS: In Alzheimer's disease genetic variation influences a number of aspects of clinical phenotype.

Entities:  

Mesh:

Year:  2002        PMID: 11823322     DOI: 10.1192/bjp.180.2.131

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  25 in total

1.  Reduced glutamate neurotransmission in patients with Alzheimer's disease -- an in vivo (13)C magnetic resonance spectroscopy study.

Authors:  Alexander P Lin; Frederick Shic; Cathleen Enriquez; Brian D Ross
Journal:  MAGMA       Date:  2003-02       Impact factor: 2.310

Review 2.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics.

Authors:  Eric Karran; Marc Mercken; Bart De Strooper
Journal:  Nat Rev Drug Discov       Date:  2011-08-19       Impact factor: 84.694

3.  Dementia: continuum or distinct entity?

Authors:  Glenn D Walters
Journal:  Psychol Aging       Date:  2010-09

Review 4.  Correlating familial Alzheimer's disease gene mutations with clinical phenotype.

Authors:  Natalie S Ryan; Martin N Rossor
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

5.  Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation.

Authors:  C Holmes; C Ballard; D Lehmann; A David Smith; H Beaumont; I N Day; M Nadeem Khan; S Lovestone; M McCulley; C M Morris; D G Munoz; K O'Brien; C Russ; T Del Ser; D Warden
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

Review 6.  Overview of the development of personalized genomic medicine and surgery.

Authors:  F Charles Brunicardi; Richard A Gibbs; David A Wheeler; John Nemunaitis; William Fisher; John Goss; Changyi Chen
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

Review 7.  New insight into neurodegeneration: the role of proteomics.

Authors:  Ramavati Pal; Guido Alves; Jan Petter Larsen; Simon Geir Møller
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

Review 8.  Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.

Authors:  J Scott Roberts; Wendy R Uhlmann
Journal:  Prog Neurobiol       Date:  2013-04-09       Impact factor: 11.685

9.  Asynchronous evolutionary origins of Aβ and BACE1.

Authors:  D Blaine Moore; Madelyn A Gillentine; Nathalie M Botezatu; Kyle A Wilson; Ashley E Benson; James A Langeland
Journal:  Mol Biol Evol       Date:  2013-12-19       Impact factor: 16.240

Review 10.  Role of cholesterol in APP metabolism and its significance in Alzheimer's disease pathogenesis.

Authors:  M Maulik; D Westaway; J H Jhamandas; S Kar
Journal:  Mol Neurobiol       Date:  2012-09-16       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.